Seeking Alpha

InterMune (ITMN +5%) rallies after Brean Murray calls it a top 2012 pick, citing a low valuation...

InterMune (ITMN +5%) rallies after Brean Murray calls it a top 2012 pick, citing a low valuation and strong German demand for InterMune's Esbriet lung disease drug. Brean's call is more than offsetting a PT cut from Goldman (Neutral), which thinks uncertainty over future Esbriet pricing "creates an overhang that is likely to persist through the middle of 2012."
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)